Hugo Fernandez, MD
Hematology · Pembroke Pines, FLNPI 1437181674
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,900 of the $30,126 with a category attached, or 66.1%. 20 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 34.0% of the total. Reporting peaked in 2019 at $17,234 and has fallen 98.4% since, to $280 in 2025.
Across 58 payments — averaging $519.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$10K
- Incyte Corporation$9K
- Sanofi$7K
- Novartis$3K
- Daiichi Sankyo Inc.$317
- Janssen Scientific Affairs, LLC$296
- plus $1K from 14 others
Across 9 payments — averaging $966.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$7K
- Novartis$2K
What the payments were for
- Consulting fees$19,90066%
- Speaking & faculty fees$6,82523%
- Travel & lodging$7783%
- Food & beverage$2,6239%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 8 | $10,234 |
| Incyte Corporation | 15 | $8,513 |
| Sanofi | 4 | $7,083 |
| Novartis | 2 | $2,628 |
| Daiichi Sankyo Inc. | 4 | $317 |
| Janssen Scientific Affairs, LLC | 5 | $296 |
| Johnson & Johnson(3 entities) | 5 | $216 |
| Stryker | 1 | $159 |
| Seagen Inc. | 2 | $105 |
| AstraZeneca | 1 | $101 |
| Stemline Therapeutics Inc. | 1 | $100 |
| Gilead | 2 | $75 |
| Sobi, Inc | 1 | $69 |
| Sanofi-aventis U.S. LLC | 1 | $68 |
| Sirtex Medical Inc | 1 | $62 |
| Teleflex LLC | 1 | $34 |
| Boehringer Ingelheim | 1 | $20 |
| Pfizer | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $14 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,126 in reported general payments places this provider in the 80th percentile of 79 hematology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 63 | $1,166,447 |
| RevlimidLenalidomide | 59 | $889,006 |
| RezurockBelumosudil Mesylate | 22 | $584,276 |
| CalquenceAcalabrutinib Maleate | 12 | $172,670 |
| TasignaNilotinib Hcl | 13 | $101,009 |
| InqoviDecitabine/Cedazuridine | 11 | $77,088 |
| VenclextaVenetoclax | 12 | $64,093 |
| EliquisApixaban | 31 | $17,985 |
| Sirolimus | 64 | $17,581 |
| Ursodiol | 35 | $1,571 |
| Acyclovir | 85 | $1,184 |
| Pilocarpine Hcl | 12 | $591 |
| Dexamethasone | 16 | $585 |
| Tenofovir Disoproxil Fumarate | 13 | $419 |
| Alendronate Sodium | 17 | $222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $8,513 | $1,166,44763 claims |
| Sanofi-aventis U.S. LLCRezurock | $68 | $584,27622 claims |
| AstraZenecaCalquence | $101 | $172,67012 claims |
| NovartisTasigna | $2,628 | $101,00913 claims |
| AbbVieVenclexta | $14 | $64,09312 claims |
| PfizerEliquis | $18 | $17,98531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 79 hematology providers in Florida.
Other hematology in Pembroke Pines
- Jennifer LoguePembroke Pines$2K
- Javier Pinilla-IbarzTampa$1.6M
- Rami KomrokjiTampa$855K
- Ahmed ZakariAltamonte Springs$383K
- Alex Mejia GarciaVero Beach$302K
- Doris HansenTampa$141K
- Juan VarelaOrlando$131K
- Firas El ChaerMiami$105K
- Philip PancariOrlando$70K
- Melissa AlsinaTampa$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.